Phase 3 Start

IKT: Phase3_Start: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial Hypertension

Name: Phase3_Start: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial Hypertension
Start: 2026-10-23
End: 2026-10-23

October 23, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 23, 2026
Company: Inhibikase Therapeutics, Inc. (IKT)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial Hypertension

October 23, 2026

IKT overview →

Company: Inhibikase Therapeutics, Inc. (IKT)